Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979 · View on ClinicalTrials.gov ↗
Study Summary
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles — Los Angeles
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed) — Los Angeles
- Children's Hospital of Orange County Main Campus - Orange — Orange
- Center Of Excellence in Diabetes and Endocrinology — Sacramento
- Rady Children's Hospital - San Diego — San Diego
- University of California San Francisco (UCSF) — San Francisco
Florida
- Nemours Children's Clinic — Jacksonville
- Nicklaus Children's Hospital — Miami
- Nemours Children's Health System - Corporate Headquarters — Pensacola
Idaho
- St. Luke's Children's Endocrinology — Boise
- Rocky Mountain Diabetes Center - Idaho Falls — Idaho Falls
- Rocky Mountain Clinical Research - Idaho Falls — Idaho Falls
Connecticut
- Connecticut Children's Medical Center — Hartford
- Yale School of Medicine — New Haven
Arizona
- Phoenix Children's Hospital - Thomas Campus (Main) — Phoenix
District of Columbia
- Children's National Health System — Washington D.C.
Georgia
- Centricity Research — Columbus
Kentucky
- University of Louisville School Of Medicine - Norton Children's Hospital — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2040-12-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06309979
The ClinicalTrials.gov registry entry for NCT06309979 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Idiopathic Short Stature appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06309979 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Idaho. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06309979 about?
NCT06309979 is a clinical study titled "A Study to Assess Growth in Children With Idiopathic Short Stature". Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
What is the current status of trial NCT06309979?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-08-08. Estimated completion is 2040-12-31.
What conditions does trial NCT06309979 study?
This clinical trial studies the following conditions: Idiopathic Short Stature. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06309979?
This trial is sponsored by BioMarin Pharmaceutical, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06309979 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.